Molecular basis of inhibition of the amino acid transporter B<sup>0</sup>AT1 (SLC6A19).
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 39174516.
- Also identified by DOI 10.1038/s41467-024-51748-1 and PMC identifier 11341722.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The epithelial neutral amino acid transporter B<sup>0</sup>AT1 (SLC6A19) is the major transporter for the absorption of neutral amino acids in the intestine and their reabsorption in the kidney. Mouse models have demonstrated that lack of B<sup>0</sup>AT1 can normalize elevated plasma amino acids in rare disorders of amino acid metabolism such as phenylketonuria and urea-cycle disorders, implying a pharmacological approach for their treatment. Here we employ a medicinal chemistry approach to generate B<sup>0</sup>AT1 inhibitors with IC<sub>50</sub>-values of 31-90 nM. High-resolution cryo-EM structures of B<sup>0</sup>AT1 in the presence of two compounds from this series identified an allosteric binding site in the vestibule of the transporter. Mechanistically, binding of these inhibitors prevents a movement of TM1 and TM6 that is required for the transporter to make a conformational change from an outward open state to the occluded state.
Medical subject headings
- Cryoelectron Microscopy
- Amino Acid Transport Systems, Neutral